Cholinergic/Adrenergic drugs — MCQs

Q: A mother reports that her daughter ingested a substance in an unknown dose. The girl presents with hypertension, tachycardia, mydriasis, and hyperthermia. What is the most likely substance?

Cocaine. ***Cocaine*** - The presented symptoms of **hypertension, tachycardia, mydriasis, and hyperthermia** are characteristic of a **sympathomimetic toxidrome**, frequently caused by cocaine overdose. - Cocaine acts as a **norepinephrine-dopamine-serotonin reuptake inhibitor**, leading to excessive stimulation of the central and peripheral nervous systems. *Heroin* - Heroin is an **opioid**, and overdose generally presents with **respiratory depression, bradycardia, miosis (pinpoint pupils)**, and hypotension, which are contrary to the patient's symptoms. - Patients typically exhibit central nervous system **depression**, rather than the hyperactive state seen here. *Morphine* - Similar to heroin, morphine is an **opioid** and causes symptoms like **respiratory depression, bradycardia, miosis**, and hypotension. - These effects are the opposite of the **sympathomimetic** signs observed in the patient. *Chlorpheniramine* - Chlorpheniramine is an **antihistamine** with significant **anticholinergic effects**. An overdose might cause **mydriasis and tachycardia**, but not typically severe hypertension or hyperthermia as the primary features. - Other anticholinergic signs such as **dry mucous membranes, urinary retention, and altered mental status (delirium)** would also be expected. *Organophosphate* - Organophosphate poisoning causes a **cholinergic toxidrome** due to **acetylcholinesterase inhibition**, resulting in excessive cholinergic stimulation. - Classic presentation includes **SLUDGE syndrome** (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis) along with **miosis (pinpoint pupils), bradycardia, bronchospasm**, and muscle fasciculations. - These findings are the **opposite** of the sympathomimetic signs seen in this patient.

Q: A 45-year-old patient with a history of depression was initially being treated with sertraline, but his symptoms were not adequately controlled. His medication regimen was changed to include an MAO inhibitor and amitriptyline. Shortly after the change in medication, the patient developed agitation, seizures, hyperreflexia, and tremor. Which of the following is the most appropriate treatment for this patient?

Cyproheptadine. ***Cyproheptadine*** - This patient exhibits symptoms of **serotonin syndrome** (agitation, seizures, hyperreflexia, tremor) due to the combination of an **MAO inhibitor** and **amitriptyline**. - **Cyproheptadine** is a **serotonin antagonist** and is the most appropriate treatment for reversing the effects of serotonin syndrome. - Treatment also includes discontinuing offending agents and supportive care. *Lorazepam* - **Lorazepam** is a **benzodiazepine** that can help manage agitation and seizures, but it does not address the underlying serotonin overstimulation. - It would be used as an adjunct for symptom control, not as the primary treatment for serotonin syndrome. *Dantrolene* - **Dantrolene** is a **muscle relaxant** used for **neuroleptic malignant syndrome (NMS)** and **malignant hyperthermia**. - While NMS and serotonin syndrome can have overlapping features (hyperthermia, rigidity), dantrolene is not indicated for serotonin syndrome. - Cyproheptadine is the specific serotonin antagonist needed for this condition. *L-carnitine* - **L-carnitine** is a supplement often used for conditions like **carnitine deficiency** or certain **metabolic disorders**. - It has no role in the treatment of serotonin syndrome. *Leucovorin* - **Leucovorin** (folinic acid) is used to **rescue bone marrow** from the toxic effects of **methotrexate** or to enhance the effects of **fluorouracil**. - It is not indicated for the treatment of serotonin syndrome.

Q: Why is atropine mixed with diphenoxylate in combination medications?

To prevent abuse of diphenoxylate. ***To prevent abuse of diphenoxylate*** - **Diphenoxylate** is an opioid derivative with potential for abuse due to its CNS effects at high doses. - Adding **atropine** discourages abuse by producing unpleasant anticholinergic side effects (e.g., dry mouth, blurred vision, urinary retention) if high doses are ingested. *Atropine decreases the adverse effects of diphenoxylate* - **Atropine** does not decrease the adverse effects of diphenoxylate; rather, it introduces its own set of **anticholinergic** side effects. - The combination is designed to make recreational use unpleasant, not to mitigate side effects of diphenoxylate itself. *To enhance the antidiarrheal effect* - While atropine has some anticholinergic properties that can reduce gut motility, its primary purpose in this combination is **not to enhance the antidiarrheal effect**. - **Diphenoxylate** is the primary antidiarrheal agent, and the amount of atropine included is typically subtherapeutic for significant antidiarrheal action. *Atropine produces direct spasmolytic action* - Although **atropine** does have **spasmolytic** effects by blocking muscarinic receptors in the gut, this is not the main reason for its addition to diphenoxylate. - The dosage of atropine in the combination is usually low enough to cause unpleasant systemic effects but not necessarily to significantly contribute to the antispasmodic action at therapeutic doses of diphenoxylate. *Atropine increases the bioavailability of diphenoxylate* - **Atropine** does not affect the **pharmacokinetics** or **bioavailability** of diphenoxylate. - The two drugs are combined for abuse deterrence purposes, not for any pharmacokinetic interaction or enhancement of drug absorption.

Q: Which of the following statements regarding the patch shown in the figure is correct?

Excessive use can result in methemoglobinemia.. ***Excessive use can result in methemoglobinemia.*** - The patch shown is likely an **EMLA patch**, which contains **lidocaine** and **prilocaine**. Excessive absorption of prilocaine, especially with large doses or prolonged application, can lead to the formation of **methemoglobinemia**. - **Prilocaine** is metabolized into **ortho-toluidine**, which is an oxidizing agent that can convert hemoglobin to methemoglobin, reducing the blood's oxygen-carrying capacity. *It is an equal mixture of local anesthetics.* - The EMLA patch is a 1:1 mixture of **lidocaine** and **prilocaine**, but the claim that it contains "an equal mixture of local anesthetics" is vague and could imply other compositions not specific to EMLA. - While it's an equal ratio of two specific local anesthetics, the option's wording is not precise enough to be the *most correct* statement. *5 ml of a 5 percent mixture contains 50 mg of lignocaine.* - A 5% solution means 5 grams (5000 mg) per 100 ml. Therefore, 1 ml contains 50 mg of lignocaine. - Thus, 5 ml of a 5% mixture would contain 250 mg of **lignocaine**, not 50 mg. This statement is mathematically incorrect. *It contains lignocaine and ropivacaine in a ratio of 50 percent each.* - **EMLA patches** contain **lidocaine** (lignocaine) and **prilocaine**, not ropivacaine. - While it is a 50% concentration for each active ingredient, the specific combination of local anesthetics mentioned in this option is incorrect. *It should be applied for at least 2 hours before minor procedures.* - For most minor procedures, **EMLA cream** typically requires **30-60 minutes** of application time to achieve adequate topical anesthesia. - While longer application times (up to 2 hours) may enhance depth of anesthesia for certain procedures, stating that it "should be applied for at least 2 hours" is excessive and not a standard recommendation for minor procedures.

Q: Which of the following is the most appropriate treatment for an overactive bladder in a patient with dementia?

Tolterodine. ***Tolterodine*** - **Tolterodine** is a **muscarinic antagonist** that blocks acetylcholine receptors in the bladder, reducing detrusor muscle contractions and overactive bladder symptoms. - Unlike some other anticholinergics like oxybutynin, it has a **lower propensity to cross the blood-brain barrier** and thus a reduced risk of exacerbating cognitive impairment in patients with dementia. *Mirabegron* - **Mirabegron** is a **beta-3 adrenergic agonist** that relaxes the detrusor muscle, increasing bladder capacity. - While it has a different mechanism of action and is less likely to cause anticholinergic cognitive side effects than older anticholinergics, it can still cause **hypertension** and **tachycardia**, which may be problematic in elderly patients with comorbidities. *Behavioral therapy/bladder training* - **Behavioral therapy** and **bladder training** are important first-line treatments for overactive bladder. - However, for patients with **dementia**, cognitive impairment often makes adherence to and understanding of these complex therapies challenging or impossible without significant caregiver support. *Oxybutynin* - **Oxybutynin** is an **anticholinergic drug** that is effective for overactive bladder. - However, it has a **high affinity for muscarinic receptors** in the brain and readily crosses the blood-brain barrier, significantly increasing the risk of **cognitive impairment, confusion, and delirium** in elderly patients, especially those with pre-existing dementia. *Trospium* - **Trospium** is a **quaternary amine anticholinergic** that is hydrophilic and has minimal blood-brain barrier penetration. - While theoretically safer than oxybutynin in terms of CNS effects, it has **lower bladder selectivity** compared to tolterodine and may cause more peripheral anticholinergic side effects (dry mouth, constipation).

Q: Caffeine impairs sleep by which of the following mechanisms?

Blocks adenosine action and promotes wakefulness. ***Blocks adenosine action and promotes wakefulness*** - Caffeine functions as a competitive **adenosine receptor antagonist**, primarily at A1 and A2A receptors in the brain. - By blocking adenosine, which is an endogenous sleep-promoting neurochemical, caffeine reduces its inhibitory effects on wakefulness centers, thus **promoting alertness** and delaying sleep onset. *Activates locus coeruleus & promotes wakefulness* - While caffeine indirectly influences brain regions that promote wakefulness, its primary mechanism is not direct activation of the **locus coeruleus**. - Its effects on wakefulness are mediated more broadly through antagonism of **adenosine receptors.** *No role in maintaining wakefulness* - This statement is incorrect; caffeine is well-known for its **psychoactive properties** and its ability to increase alertness and reduce fatigue. - Its widespread consumption is largely attributed to its role in **promoting wakefulness** and improving cognitive function. *Activates histamine release and prevents sleep* - Caffeine does not significantly activate **histamine release** as a primary mechanism for its wake-promoting effects. - The wake-promoting effects of histamine are mediated via H1 receptors, but this is a separate pathway not directly targeted by caffeine. *Inhibits phosphodiesterase and increases cAMP levels* - While caffeine does inhibit **phosphodiesterase enzymes** (particularly at higher concentrations), this is not the primary mechanism for its wake-promoting effects. - The concentrations required for significant phosphodiesterase inhibition are much higher than those achieved with typical caffeine consumption; **adenosine receptor antagonism** occurs at much lower doses and is the dominant mechanism for its effects on sleep and alertness.

Q: A Myasthenia Gravis patient on mycophenolate and pyridostigmine presents with hypercalcemia. Apart from the obvious drug-related cause, what other condition could be associated with hypercalcemia in this patient?

Non-Small Cell Lung Cancer (NSCLC). ***Non-Small Cell Lung Cancer (NSCLC)*** - **Hypercalcemia of malignancy** is a common paraneoplastic syndrome in NSCLC, particularly squamous cell carcinoma, due to the production of **parathyroid hormone-related protein (PTHrP)**. - Patients with myasthenia gravis, especially those with thymoma, have an increased risk of developing other malignancies, including lung cancer, making this an important consideration. *Drug induced* - While certain medications can cause hypercalcemia, the question specifically asks for a condition **apart from the obvious drug-related cause**. - Medications like **thiazide diuretics**, **lithium**, or excessive **vitamin D** supplementation are known causes of hypercalcemia. *Parathyroid adenoma* - A parathyroid adenoma causes **primary hyperparathyroidism**, characterized by elevated PTH and hypercalcemia. - While possible, the association with myasthenia gravis and the increased risk of malignancy make **paraneoplastic syndrome** a more contextual answer here given the prompt. *Small Cell Lung Cancer (SCLC)* - SCLC is more commonly associated with other paraneoplastic syndromes like **SIADH (syndrome of inappropriate antidiuretic hormone secretion)** due to ectopic ADH production, or **Cushing's syndrome** due to ectopic ACTH production. - While hypercalcemia can rarely occur, it is **less common** and typically not due to PTHrP in SCLC compared to NSCLC. *Sarcoidosis* - Sarcoidosis can cause hypercalcemia through increased production of **1,25-dihydroxyvitamin D** by activated macrophages in granulomas, leading to enhanced intestinal calcium absorption. - However, in the context of a myasthenia gravis patient with the clinical scenario described, **malignancy-associated hypercalcemia** (particularly NSCLC) is a more likely and clinically relevant consideration.

A 30-year-old drug addict presents to the emergency department with signs of unknown drug poisoning. The patient exhibits dilated pupils, diaphoresis, tachycardia, and tremors. On examination, the blood pressure is 180/110 mmHg, and the heart rate is 120 beats per minute. What is the most likely diagnosis?

A 45-year-old patient with a history of depression was initially being treated with sertraline, but his symptoms were not adequately controlled. His medication regimen was changed to include an MAO inhibitor and amitriptyline. Shortly after the change in medication, the patient developed agitation, seizures, hyperreflexia, and tremor. Which of the following is the most appropriate treatment for this patient?

Which of the following is a selective norepinephrine reuptake inhibitor that can be used for the treatment of ADHD?

Why is atropine mixed with diphenoxylate in combination medications?

Which of the following statements regarding the patch shown in the figure is correct?

Which of the following is the most appropriate treatment for an overactive bladder in a patient with dementia?

Caffeine impairs sleep by which of the following mechanisms?

Q10

A Myasthenia Gravis patient on mycophenolate and pyridostigmine presents with hypercalcemia. Apart from the obvious drug-related cause, what other condition could be associated with hypercalcemia in this patient?

Cholinergic/Adrenergic drugs US Medical PG Practice Questions and MCQs

Question 1: A chronic smoker wants to quit smoking. Which of the following is the MOST appropriate first-line pharmacotherapy for smoking cessation?

A. Mirtazapine
B. Varenicline (Correct Answer)
C. Bupropion
D. Nicotine replacement therapy
E. Clonidine

Explanation: ***Varenicline*** - **Varenicline** is a **partial agonist** at the **α4β2 nicotinic acetylcholine receptor**, the primary receptor involved in nicotine addiction. - It reduces cravings and withdrawal symptoms while blocking the reinforcing effects of nicotine from cigarettes. - Studies show **varenicline has the highest efficacy** among pharmacological agents for smoking cessation, with superior quit rates compared to bupropion and NRT. - **First-line agent** recommended by clinical guidelines for smoking cessation. *Mirtazapine* - Mirtazapine is a **tetracyclic antidepressant** (α2-antagonist, 5-HT2 and 5-HT3 antagonist) used for **major depressive disorder**. - **Not indicated** for smoking cessation and lacks evidence for efficacy in this context. - May cause weight gain and sedation, which are not beneficial for smoking cessation. *Bupropion* - **Bupropion** is an **atypical antidepressant** and **norepinephrine-dopamine reuptake inhibitor (NDRI)** that also antagonizes nicotinic receptors. - Effective **first-line agent** for smoking cessation, reducing cravings and withdrawal symptoms. - However, studies show **lower efficacy compared to varenicline** in head-to-head trials. - Contraindicated in patients with seizure disorders or eating disorders. *Nicotine replacement therapy* - **NRT** (patches, gum, lozenges, inhalers, nasal spray) provides controlled nicotine delivery without harmful tobacco combustion products. - Effective **first-line therapy** that reduces withdrawal symptoms and cravings. - Generally **less effective than varenicline** when used alone, but can be combined with other therapies. - Safest option with minimal contraindications. *Clonidine* - **Clonidine** is a **central α2-agonist** primarily used for hypertension. - Considered a **second-line agent** for smoking cessation, used only when first-line therapies fail or are contraindicated. - Less effective than first-line agents and associated with more adverse effects (sedation, dry mouth, hypotension). - Not routinely recommended for smoking cessation.

Question 2: A mother reports that her daughter ingested a substance in an unknown dose. The girl presents with hypertension, tachycardia, mydriasis, and hyperthermia. What is the most likely substance?

A. Heroin
B. Morphine
C. Cocaine (Correct Answer)
D. Chlorpheniramine
E. Organophosphate

Explanation: ***Cocaine*** - The presented symptoms of **hypertension, tachycardia, mydriasis, and hyperthermia** are characteristic of a **sympathomimetic toxidrome**, frequently caused by cocaine overdose. - Cocaine acts as a **norepinephrine-dopamine-serotonin reuptake inhibitor**, leading to excessive stimulation of the central and peripheral nervous systems. *Heroin* - Heroin is an **opioid**, and overdose generally presents with **respiratory depression, bradycardia, miosis (pinpoint pupils)**, and hypotension, which are contrary to the patient's symptoms. - Patients typically exhibit central nervous system **depression**, rather than the hyperactive state seen here. *Morphine* - Similar to heroin, morphine is an **opioid** and causes symptoms like **respiratory depression, bradycardia, miosis**, and hypotension. - These effects are the opposite of the **sympathomimetic** signs observed in the patient. *Chlorpheniramine* - Chlorpheniramine is an **antihistamine** with significant **anticholinergic effects**. An overdose might cause **mydriasis and tachycardia**, but not typically severe hypertension or hyperthermia as the primary features. - Other anticholinergic signs such as **dry mucous membranes, urinary retention, and altered mental status (delirium)** would also be expected. *Organophosphate* - Organophosphate poisoning causes a **cholinergic toxidrome** due to **acetylcholinesterase inhibition**, resulting in excessive cholinergic stimulation. - Classic presentation includes **SLUDGE syndrome** (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis) along with **miosis (pinpoint pupils), bradycardia, bronchospasm**, and muscle fasciculations. - These findings are the **opposite** of the sympathomimetic signs seen in this patient.

Question 3: A 30-year-old drug addict presents to the emergency department with signs of unknown drug poisoning. The patient exhibits dilated pupils, diaphoresis, tachycardia, and tremors. On examination, the blood pressure is 180/110 mmHg, and the heart rate is 120 beats per minute. What is the most likely diagnosis?

A. Cocaine intoxication (Correct Answer)
B. Dhatura poisoning
C. Cannabis poisoning
D. Alcohol intoxication
E. Amphetamine intoxication

Explanation: ***Cocaine intoxication*** - Cocaine is a potent **sympathomimetic** drug that leads to a hyperadrenergic state, causing symptoms like **dilated pupils**, diaphoresis, tachycardia, and hypertension. - The patient's presentation with significant **tachycardia (120 bpm)** and **hypertension (180/110 mmHg)**, along with a history of drug abuse, strongly points towards cocaine. - Cocaine has a **shorter duration of action** (30-90 minutes) compared to amphetamines, but the clinical presentation is nearly identical. *Amphetamine intoxication* - **Amphetamines** also cause a sympathomimetic toxidrome very similar to cocaine, with mydriasis, diaphoresis, tachycardia, and hypertension. - However, the acute presentation is clinically indistinguishable from cocaine, though amphetamines typically have a **longer duration of action** (4-8 hours). - Both diagnoses would be managed similarly in the acute setting. *Dhatura poisoning* - **Dhatura** causes an **anticholinergic toxidrome**, characterized by symptoms such as "hot, dry, blind, red, and mad." - Key features of dhatura poisoning include **dry mucous membranes**, dilated pupils (mydriasis), flushed skin, but typically a **normal or elevated temperature** rather than diaphoresis and less pronounced hypertension. *Cannabis poisoning* - **Cannabis intoxication** typically leads to symptoms like **conjunctival injection**, dry mouth, increased appetite, and impaired coordination. - While it can cause mild tachycardia, it generally does not result in the severe **hypertension**, profound diaphoresis, or significant tremors seen in this patient. *Alcohol intoxication* - **Alcohol intoxication** usually presents with central nervous system depression, such as **slurred speech**, ataxia, nystagmus, and drowsiness. - While alcohol can affect blood pressure and heart rate, it typically causes **hypotension** or mild hypertension, and it does not produce the marked sympathomimetic effects such as **mydriasis** and profound diaphoresis observed here.

Question 4: A 45-year-old patient with a history of depression was initially being treated with sertraline, but his symptoms were not adequately controlled. His medication regimen was changed to include an MAO inhibitor and amitriptyline. Shortly after the change in medication, the patient developed agitation, seizures, hyperreflexia, and tremor. Which of the following is the most appropriate treatment for this patient?

A. Cyproheptadine (Correct Answer)
B. Lorazepam
C. L-carnitine
D. Leucovorin
E. Dantrolene

Explanation: ***Cyproheptadine*** - This patient exhibits symptoms of **serotonin syndrome** (agitation, seizures, hyperreflexia, tremor) due to the combination of an **MAO inhibitor** and **amitriptyline**. - **Cyproheptadine** is a **serotonin antagonist** and is the most appropriate treatment for reversing the effects of serotonin syndrome. - Treatment also includes discontinuing offending agents and supportive care. *Lorazepam* - **Lorazepam** is a **benzodiazepine** that can help manage agitation and seizures, but it does not address the underlying serotonin overstimulation. - It would be used as an adjunct for symptom control, not as the primary treatment for serotonin syndrome. *Dantrolene* - **Dantrolene** is a **muscle relaxant** used for **neuroleptic malignant syndrome (NMS)** and **malignant hyperthermia**. - While NMS and serotonin syndrome can have overlapping features (hyperthermia, rigidity), dantrolene is not indicated for serotonin syndrome. - Cyproheptadine is the specific serotonin antagonist needed for this condition. *L-carnitine* - **L-carnitine** is a supplement often used for conditions like **carnitine deficiency** or certain **metabolic disorders**. - It has no role in the treatment of serotonin syndrome. *Leucovorin* - **Leucovorin** (folinic acid) is used to **rescue bone marrow** from the toxic effects of **methotrexate** or to enhance the effects of **fluorouracil**. - It is not indicated for the treatment of serotonin syndrome.

Question 5: Which of the following is a selective norepinephrine reuptake inhibitor that can be used for the treatment of ADHD?

A. Reboxetine
B. Methylphenidate
C. Guanfacine
D. Modafinil
E. Atomoxetine (Correct Answer)

Explanation: ***Atomoxetine*** - **Atomoxetine** is a **selective norepinephrine reuptake inhibitor (SNRI)** that is **FDA-approved specifically for the treatment of ADHD** in children, adolescents, and adults. - It works by **selectively blocking the presynaptic norepinephrine transporter**, increasing norepinephrine availability in the prefrontal cortex and other brain regions involved in attention and impulse control. - Unlike stimulant medications, atomoxetine is **not a controlled substance** and is considered a first-line **non-stimulant option** for ADHD treatment. - It is particularly useful in patients with comorbid anxiety, tic disorders, or substance abuse concerns. *Reboxetine* - While **reboxetine** is technically a **selective norepinephrine reuptake inhibitor**, it is primarily used as an **antidepressant** and is **not approved for ADHD treatment**. - It has been investigated off-label for ADHD, but it is not a standard or recommended treatment option. - Reboxetine has **limited global availability** and has been withdrawn from many markets due to efficacy concerns. *Methylphenidate* - **Methylphenidate** is a **stimulant** medication that inhibits the reuptake of both **dopamine and norepinephrine**, making it **non-selective**. - It is a first-line treatment for ADHD, but its mechanism of action involves dual monoamine reuptake inhibition, not selective norepinephrine reuptake. *Guanfacine* - **Guanfacine** is an **alpha-2 adrenergic agonist**, not a norepinephrine reuptake inhibitor. - It works by stimulating postsynaptic alpha-2A receptors in the prefrontal cortex, which enhances prefrontal cortex function and improves attention and impulse control. *Modafinil* - **Modafinil** is a wakefulness-promoting agent with a **complex, non-selective mechanism** involving dopamine, norepinephrine, histamine, and orexin systems. - It is primarily used for **narcolepsy** and excessive daytime sleepiness, not as a primary ADHD treatment. - It is **not classified as a selective norepinephrine reuptake inhibitor**.

Question 6: Why is atropine mixed with diphenoxylate in combination medications?

A. Atropine decreases the adverse effects of diphenoxylate
B. To prevent abuse of diphenoxylate (Correct Answer)
C. To enhance the antidiarrheal effect
D. Atropine produces direct spasmolytic action
E. Atropine increases the bioavailability of diphenoxylate

Explanation: ***To prevent abuse of diphenoxylate*** - **Diphenoxylate** is an opioid derivative with potential for abuse due to its CNS effects at high doses. - Adding **atropine** discourages abuse by producing unpleasant anticholinergic side effects (e.g., dry mouth, blurred vision, urinary retention) if high doses are ingested. *Atropine decreases the adverse effects of diphenoxylate* - **Atropine** does not decrease the adverse effects of diphenoxylate; rather, it introduces its own set of **anticholinergic** side effects. - The combination is designed to make recreational use unpleasant, not to mitigate side effects of diphenoxylate itself. *To enhance the antidiarrheal effect* - While atropine has some anticholinergic properties that can reduce gut motility, its primary purpose in this combination is **not to enhance the antidiarrheal effect**. - **Diphenoxylate** is the primary antidiarrheal agent, and the amount of atropine included is typically subtherapeutic for significant antidiarrheal action. *Atropine produces direct spasmolytic action* - Although **atropine** does have **spasmolytic** effects by blocking muscarinic receptors in the gut, this is not the main reason for its addition to diphenoxylate. - The dosage of atropine in the combination is usually low enough to cause unpleasant systemic effects but not necessarily to significantly contribute to the antispasmodic action at therapeutic doses of diphenoxylate. *Atropine increases the bioavailability of diphenoxylate* - **Atropine** does not affect the **pharmacokinetics** or **bioavailability** of diphenoxylate. - The two drugs are combined for abuse deterrence purposes, not for any pharmacokinetic interaction or enhancement of drug absorption.

Question 7: Which of the following statements regarding the patch shown in the figure is correct?

A. It is an equal mixture of local anesthetics.
B. Excessive use can result in methemoglobinemia. (Correct Answer)
C. 5 ml of a 5 percent mixture contains 50 mg of lignocaine.
D. It contains lignocaine and ropivacaine in a ratio of 50 percent each.
E. It should be applied for at least 2 hours before minor procedures.

Explanation: ***Excessive use can result in methemoglobinemia.*** - The patch shown is likely an **EMLA patch**, which contains **lidocaine** and **prilocaine**. Excessive absorption of prilocaine, especially with large doses or prolonged application, can lead to the formation of **methemoglobinemia**. - **Prilocaine** is metabolized into **ortho-toluidine**, which is an oxidizing agent that can convert hemoglobin to methemoglobin, reducing the blood's oxygen-carrying capacity. *It is an equal mixture of local anesthetics.* - The EMLA patch is a 1:1 mixture of **lidocaine** and **prilocaine**, but the claim that it contains "an equal mixture of local anesthetics" is vague and could imply other compositions not specific to EMLA. - While it's an equal ratio of two specific local anesthetics, the option's wording is not precise enough to be the *most correct* statement. *5 ml of a 5 percent mixture contains 50 mg of lignocaine.* - A 5% solution means 5 grams (5000 mg) per 100 ml. Therefore, 1 ml contains 50 mg of lignocaine. - Thus, 5 ml of a 5% mixture would contain 250 mg of **lignocaine**, not 50 mg. This statement is mathematically incorrect. *It contains lignocaine and ropivacaine in a ratio of 50 percent each.* - **EMLA patches** contain **lidocaine** (lignocaine) and **prilocaine**, not ropivacaine. - While it is a 50% concentration for each active ingredient, the specific combination of local anesthetics mentioned in this option is incorrect. *It should be applied for at least 2 hours before minor procedures.* - For most minor procedures, **EMLA cream** typically requires **30-60 minutes** of application time to achieve adequate topical anesthesia. - While longer application times (up to 2 hours) may enhance depth of anesthesia for certain procedures, stating that it "should be applied for at least 2 hours" is excessive and not a standard recommendation for minor procedures.

Question 8: Which of the following is the most appropriate treatment for an overactive bladder in a patient with dementia?

A. Tolterodine (Correct Answer)
B. Mirabegron
C. Behavioral therapy/bladder training
D. Oxybutynin
E. Trospium

Explanation: ***Tolterodine*** - **Tolterodine** is a **muscarinic antagonist** that blocks acetylcholine receptors in the bladder, reducing detrusor muscle contractions and overactive bladder symptoms. - Unlike some other anticholinergics like oxybutynin, it has a **lower propensity to cross the blood-brain barrier** and thus a reduced risk of exacerbating cognitive impairment in patients with dementia. *Mirabegron* - **Mirabegron** is a **beta-3 adrenergic agonist** that relaxes the detrusor muscle, increasing bladder capacity. - While it has a different mechanism of action and is less likely to cause anticholinergic cognitive side effects than older anticholinergics, it can still cause **hypertension** and **tachycardia**, which may be problematic in elderly patients with comorbidities. *Behavioral therapy/bladder training* - **Behavioral therapy** and **bladder training** are important first-line treatments for overactive bladder. - However, for patients with **dementia**, cognitive impairment often makes adherence to and understanding of these complex therapies challenging or impossible without significant caregiver support. *Oxybutynin* - **Oxybutynin** is an **anticholinergic drug** that is effective for overactive bladder. - However, it has a **high affinity for muscarinic receptors** in the brain and readily crosses the blood-brain barrier, significantly increasing the risk of **cognitive impairment, confusion, and delirium** in elderly patients, especially those with pre-existing dementia. *Trospium* - **Trospium** is a **quaternary amine anticholinergic** that is hydrophilic and has minimal blood-brain barrier penetration. - While theoretically safer than oxybutynin in terms of CNS effects, it has **lower bladder selectivity** compared to tolterodine and may cause more peripheral anticholinergic side effects (dry mouth, constipation).

Question 9: Caffeine impairs sleep by which of the following mechanisms?

A. Blocks adenosine action and promotes wakefulness (Correct Answer)
B. Activates locus coeruleus & promotes wakefulness
C. No role in maintaining wakefulness
D. Activates histamine release and prevents sleep
E. Inhibits phosphodiesterase and increases cAMP levels

Explanation: ***Blocks adenosine action and promotes wakefulness*** - Caffeine functions as a competitive **adenosine receptor antagonist**, primarily at A1 and A2A receptors in the brain. - By blocking adenosine, which is an endogenous sleep-promoting neurochemical, caffeine reduces its inhibitory effects on wakefulness centers, thus **promoting alertness** and delaying sleep onset. *Activates locus coeruleus & promotes wakefulness* - While caffeine indirectly influences brain regions that promote wakefulness, its primary mechanism is not direct activation of the **locus coeruleus**. - Its effects on wakefulness are mediated more broadly through antagonism of **adenosine receptors.** *No role in maintaining wakefulness* - This statement is incorrect; caffeine is well-known for its **psychoactive properties** and its ability to increase alertness and reduce fatigue. - Its widespread consumption is largely attributed to its role in **promoting wakefulness** and improving cognitive function. *Activates histamine release and prevents sleep* - Caffeine does not significantly activate **histamine release** as a primary mechanism for its wake-promoting effects. - The wake-promoting effects of histamine are mediated via H1 receptors, but this is a separate pathway not directly targeted by caffeine. *Inhibits phosphodiesterase and increases cAMP levels* - While caffeine does inhibit **phosphodiesterase enzymes** (particularly at higher concentrations), this is not the primary mechanism for its wake-promoting effects. - The concentrations required for significant phosphodiesterase inhibition are much higher than those achieved with typical caffeine consumption; **adenosine receptor antagonism** occurs at much lower doses and is the dominant mechanism for its effects on sleep and alertness.

Question 10: A Myasthenia Gravis patient on mycophenolate and pyridostigmine presents with hypercalcemia. Apart from the obvious drug-related cause, what other condition could be associated with hypercalcemia in this patient?

A. Drug induced
B. Parathyroid adenoma
C. Small Cell Lung Cancer (SCLC)
D. Non-Small Cell Lung Cancer (NSCLC) (Correct Answer)
E. Sarcoidosis

Explanation: ***Non-Small Cell Lung Cancer (NSCLC)*** - **Hypercalcemia of malignancy** is a common paraneoplastic syndrome in NSCLC, particularly squamous cell carcinoma, due to the production of **parathyroid hormone-related protein (PTHrP)**. - Patients with myasthenia gravis, especially those with thymoma, have an increased risk of developing other malignancies, including lung cancer, making this an important consideration. *Drug induced* - While certain medications can cause hypercalcemia, the question specifically asks for a condition **apart from the obvious drug-related cause**. - Medications like **thiazide diuretics**, **lithium**, or excessive **vitamin D** supplementation are known causes of hypercalcemia. *Parathyroid adenoma* - A parathyroid adenoma causes **primary hyperparathyroidism**, characterized by elevated PTH and hypercalcemia. - While possible, the association with myasthenia gravis and the increased risk of malignancy make **paraneoplastic syndrome** a more contextual answer here given the prompt. *Small Cell Lung Cancer (SCLC)* - SCLC is more commonly associated with other paraneoplastic syndromes like **SIADH (syndrome of inappropriate antidiuretic hormone secretion)** due to ectopic ADH production, or **Cushing's syndrome** due to ectopic ACTH production. - While hypercalcemia can rarely occur, it is **less common** and typically not due to PTHrP in SCLC compared to NSCLC. *Sarcoidosis* - Sarcoidosis can cause hypercalcemia through increased production of **1,25-dihydroxyvitamin D** by activated macrophages in granulomas, leading to enhanced intestinal calcium absorption. - However, in the context of a myasthenia gravis patient with the clinical scenario described, **malignancy-associated hypercalcemia** (particularly NSCLC) is a more likely and clinically relevant consideration.

Practice by Chapter

Acetylcholine receptors and function

Practice Questions

Cholinergic agonists (direct and indirect)

Practice Questions

Muscarinic antagonists

Practice Questions

Nicotinic antagonists

Practice Questions

Neuromuscular blocking agents

Practice Questions

Adrenergic receptor subtypes

Practice Questions

Alpha-adrenergic agonists

Practice Questions

Beta-adrenergic agonists

Practice Questions

Alpha-adrenergic antagonists

Practice Questions

Beta-adrenergic antagonists

Practice Questions

Sympathomimetics

Practice Questions

Autonomic drug interactions

Practice Questions

Clinical applications in autonomic disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free